SPH1 Antibody

What is SPHK1 and what biological functions does it regulate?

SPHK1 (Sphingosine Kinase 1) is a cytosolic or membrane-associated enzyme that catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P). It is one of two sphingosine kinases expressed in human cells, with SPHK1 and SPHK2 sharing considerable amino acid sequence similarity but differing in their N-terminal and central regions. These enzymes also have distinct tissue distribution patterns and kinetic properties. S1P functions as a lipid messenger that regulates diverse physiological processes including cell proliferation and immune modulation. The SPHK1 pathway is particularly important in cellular signaling networks related to inflammation, cancer progression, and immune regulation .

What are the recommended storage conditions for SPHK1 antibodies?

For optimal preservation of SPHK1 antibody function, the following storage conditions are recommended:

• 12 months from date of receipt at -20 to -70°C in the supplied state

• 1 month at 2 to 8°C under sterile conditions after reconstitution

• 6 months at -20 to -70°C under sterile conditions after reconstitution

It is critical to use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain antibody integrity and performance. These conditions are essential for preserving epitope recognition and binding specificity in experimental applications .

How can I detect SPHK1 in different cell lines using immunocytochemistry?

SPHK1 can be detected using immunofluorescent staining with specific protocols to ensure optimal results:

Recommended Protocol:

• Fix cells using immersion fixation technique

• Apply Mouse Anti-Human SPHK1 Monoclonal Antibody (e.g., MAB55361) at 8 μg/mL

• Incubate for 3 hours at room temperature

• Visualize using secondary antibody (e.g., NorthernLights™ 557-conjugated Anti-Mouse IgG)

• Counterstain with DAPI to visualize nuclei

This approach has successfully demonstrated specific staining localized to both nuclei and cytoplasm in HepG2 human hepatocellular carcinoma cells (positive stain), while U266 human myeloma cells serve as a negative control. Differential expression patterns across cell lines provide important internal controls for antibody specificity validation .

What is the role of SPHK1 in tumor immune evasion mechanisms?

SPHK1 functions as a critical regulator of tumor immune evasion through multiple mechanisms:

• PD-L1 Regulation: SPHK1 transcriptionally regulates tumor PD-L1 expression through the metastasis-associated protein MTA3 pathway

• Immunosuppressive Microenvironment: The SPHK1-MTA3 axis maintains immunosuppressive status in the tumor microenvironment

• Immune Cell Modulation: SPHK1 expression positively correlates with infiltration of regulatory T cells (median Rs = 0.36), myeloid-derived suppressor cells (median Rs = 0.37), and tumor-associated macrophages (median Rs = 0.32) across 33 cancer types

Functionally, inhibition of SPHK1 significantly suppresses tumor growth by promoting antitumor immunity in immunocompetent melanoma mouse models and tumor T-cell cocultures. The mechanistic analysis reveals that SPHK1's immunosuppressive effects are mediated through positive regulation of PD-L1 on melanoma cells, decreased tumor-infiltrating lymphocytes, and inhibition of tumor-specific CTL activation .

How does SPHK1 expression correlate with immune checkpoint molecules across cancer types?

SPHK1 expression demonstrates significant correlation patterns with immune checkpoint molecules across various cancer types:

Correlation Analysis Findings:

• Strong positive correlations between SPHK1 and multiple inhibitory immune checkpoint molecules were observed across 33 human cancer types

• PD-1 (encoded by PDCD1) and PD-L1 (encoded by CD274) show particularly strong correlations with SPHK1 expression

• This relationship is especially prominent in skin cutaneous melanoma (SKCM)

This correlation pattern suggests that SPHK1 possesses broad immunomodulatory potential, reflected by changes in tumor-infiltrating immune cells and increased levels of inhibitory checkpoints in the tumor microenvironment. These findings highlight SPHK1 as a potential target for combination immunotherapy strategies .

Can SPHK1 expression predict response to immune checkpoint blockade therapy?

Recent evidence strongly suggests SPHK1 expression has predictive value for immunotherapy response:

Melanoma patients treated with PD-1 blockade therapies demonstrated significantly different outcomes based on SPHK1 expression levels:

• Patients with high SPHK1 expression exhibited prolonged progression-free survival (PFS) with a hazard ratio of 0.30 (95% CI: 0.13–0.72)

• Similar benefits were observed in patients with high MTA3 expression (HR 0.44, 0.20–0.95)

• High PD-L1 expression also correlated with better outcomes (HR 0.33, 0.14–0.80)

These clinical observations align with preclinical findings showing that anti-PD-1 monoclonal antibody treatment significantly rescued tumor immune evasion mediated by SPHK1 or MTA3 overexpression. The SPHK1-MTA3 axis represents a promising biomarker for patient selection and treatment stratification in melanoma immunotherapy .

What methodological approaches are recommended for validating SPHK1 antibodies?

Thorough validation of SPHK1 antibodies requires a multi-faceted approach:

• Positive and Negative Controls: Use cell lines with known SPHK1 expression levels (e.g., HepG2 as positive, U266 as negative control)

• Multiple Detection Methods: Validate using both immunocytochemistry and western blot techniques

• Epitope Specificity Testing: Compare antibody performance against recombinant SPHK1 (e.g., S. frugiperda-derived recombinant human SPHK1 with known amino acid range Asp2-Leu398)

• Cross-Reactivity Assessment: Test for potential cross-reactivity with SPHK2 due to sequence similarities

• Subcellular Localization Verification: Confirm detection in both cytoplasmic and nuclear compartments

How does the SPHK1-MTA3 axis influence melanoma progression and therapy response?

The SPHK1-MTA3 signaling pathway represents a novel mechanism in melanoma biology:

Mechanism of Action:

• MTA3 functions as a downstream target of SPHK1 in transcriptionally regulating tumor PD-L1

• This regulatory axis establishes immunosuppression in the tumor microenvironment

• High expression of both SPHK1 and MTA3 sensitizes melanoma cells to anti-PD-1 antibody-mediated tumor cytotoxicity

Clinical Significance:

• Melanoma patients with high SPHK1-MTA3 expression show significantly better outcomes with anti-PD-1 therapy

• This axis serves as a molecular signature that can predict patient response to immunotherapy

• Targeting this pathway could potentially enhance the efficacy of existing immunotherapeutic approaches

This research demonstrates how SPHK1 transcriptionally regulates tumor PD-L1 through MTA3, revealing a novel mechanism of immune evasion in melanoma that can be therapeutically exploited .

What are the technical considerations for developing high-throughput antibody screening platforms for SPHK1?

Advanced antibody characterization requires sophisticated screening approaches:

• Phenotype-Genotype Linkage: Develop systems where each antibody is covalently linked to its encoding RNA molecule

• Selection Strategy: Design targeted selection methodologies against specific SPHK1 epitopes

• Sequencing Validation: Implement PacBio or similar deep sequencing to quantify enrichment during selection

• Reproducibility Testing: Ensure high correlation between biological replicates (e.g., Pearson correlation coefficients >0.90)

• Structural Characterization: Consider cryo-EM or other structural biology approaches to verify binding modes and epitope recognition

These high-throughput approaches accelerate antibody characterization while enabling unbiased discovery of novel SPHK1-targeting antibodies with diverse functional properties. Reproducibility between biological replicates serves as a critical quality control metric for selection processes .

What experimental approaches can be used to study SPHK1's role in immunotherapy resistance?

Investigating SPHK1's contribution to immunotherapy resistance requires multifaceted experimental strategies:

Recommended Experimental Approaches:

• Genetic Manipulation Studies:

  • CRISPR-Cas9 knockout of SPHK1 in tumor cell lines

  • Overexpression models to confirm phenotypic effects

  • Generation of MTA3-deficient lines to validate the SPHK1-MTA3-PD-L1 axis

• In Vivo Models:

  • Immunocompetent melanoma mouse models treated with SPHK1 inhibitors

  • Combination therapy experiments with anti-PD-1 antibodies

  • Tumor infiltrating lymphocyte (TIL) analysis post-treatment

• Clinical Sample Analysis:

  • Stratification of patient samples based on SPHK1/MTA3 expression

  • Correlation of expression levels with progression-free survival

  • Multiplex immunohistochemistry to assess immune cell infiltration

This comprehensive approach enables researchers to establish causality between SPHK1 expression and immunotherapy outcomes while identifying potential therapeutic vulnerabilities .

How can researchers optimize SPHK1 detection in complex tissue samples?

Detection of SPHK1 in heterogeneous tissue samples presents unique challenges requiring specific optimization:

• Fixation Methods: Compare paraformaldehyde, methanol, and acetone fixation to determine optimal epitope preservation

• Antigen Retrieval: Test various pH conditions and retrieval buffers to maximize signal-to-noise ratio

• Antibody Titration: Perform careful dilution series (starting at recommended 8 μg/mL) to identify optimal concentration

• Multiplex Imaging: Combine SPHK1 detection with lineage markers to characterize expression in specific cell populations

• Signal Amplification: Consider tyramide signal amplification for low-expression samples

Researchers should validate results using multiple antibody clones targeting different SPHK1 epitopes and include appropriate positive controls (e.g., HepG2 cells) embedded within tissue sections to ensure technical reliability .